Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + radiotherapy (Merck KGaA)
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab + RT is a combination therapeutic regimen consisting of the EGFR-targeting monoclonal antibody cetuximab and ionizing radiation (radiotherapy). Cetuximab is a chimeric IgG1 monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor (EGFR), which is frequently overexpressed in squamous cell carcinoma of the head and neck (SCCHN). By blocking ligand binding, cetuximab inhibits downstream signaling pathways involved in cell proliferation and survival, induces receptor internalization, and promotes antibody-dependent cell-mediated cytotoxicity (ADCC). When combined with radiotherapy, cetuximab acts as a radiosensitizer, enhancing the anti-tumor effects of radiation. This regimen is specifically indicated for the treatment of locally advanced SCCHN.
- Brand names
- Erbitux
- Other names
- cetuximab + RTcetuximab plus radiotherapy
02
Targets
Beyond the preview
Go deeper on cetuximab + radiotherapy (Merck KGaA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + radiotherapy (Merck KGaA).